alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › randomized-trials

randomized-trials

2 studies tagged randomized-trials, dated 2026-06-23 to 2026-07-11. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Comparative risk of amyloid-related imaging abnormalities with anti-amyloid-β monoclonal antibodies: A systematic review and penalized likelihood network meta-analysis of randomized trials 2026-07-11
  2. Pharmacological and Clinical Heterogeneity of Anti-Amyloid Monoclonal Antibodies in Early Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Trials 2026-06-23

Studies

2 studies carry this tag.

Date range

2026

Top journals

  • Journal of Alzheimer's disease : JAD 1
  • Medical sciences (Basel, Switzerland) 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Comparative risk of amyloid-related imaging abnormalities with anti-amyloid-β monoclonal antibodies: A systematic review and penalized likelihood network meta-analysis of randomized trials

    ✓ Peer-reviewed alzhub usefulness score 88 out of 100. Journal of Alzheimer's disease : JAD 2026-07-11 Treatments

    BackgroundAnti-amyloid-β monoclonal antibodies represent a new class of disease-modifying therapies for Alzheimer's disease (AD).

  2. Pharmacological and Clinical Heterogeneity of Anti-Amyloid Monoclonal Antibodies in Early Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Trials

    ✓ Peer-reviewed alzhub usefulness score 84 out of 100. Medical sciences (Basel, Switzerland) 2026-06-23 Treatments

    Six randomized comparisons derived from four phase III trials involving 7695 participants met the eligibility criteria.

All topic tags with their study counts